These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 19638456)

  • 21. VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.
    English BC; Price DK; Figg WD
    Cancer Biol Ther; 2009 Jul; 8(13):1214-25. PubMed ID: 19483467
    [No Abstract]   [Full Text] [Related]  

  • 22. The role of angiogenesis inhibitors in prostate cancer.
    Aragon-Ching JB; Dahut WL
    Cancer J; 2008; 14(1):20-5. PubMed ID: 18303479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Angiogenesis regulated by VEGF and its receptors and its clinical application.
    Shibuya M
    Rinsho Ketsueki; 2009 May; 50(5):404-12. PubMed ID: 19483401
    [No Abstract]   [Full Text] [Related]  

  • 24. [Angiogenesis inhibition: review of the activity of sorafenib, sunitinib and bevacizumab].
    Barrascout E; Medioni J; Scotte F; Ayllon J; Mejean A; Cuenod CA; Tartour E; Elaidi R; Oudard S
    Bull Cancer; 2010; 97():29-43. PubMed ID: 20418202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
    Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
    Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents.
    Desai AA; Stadler WM
    Curr Oncol Rep; 2005 Mar; 7(2):116-22. PubMed ID: 15717945
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives.
    Shen YC; Hsu C; Cheng AL
    J Gastroenterol; 2010 Aug; 45(8):794-807. PubMed ID: 20567987
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Agrin Mediates Angiogenesis in the Tumor Microenvironment.
    Chakraborty S; Njah K; Hong W
    Trends Cancer; 2020 Feb; 6(2):81-85. PubMed ID: 32061308
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progress in the management of advanced renal cell carcinoma (RCC).
    Tong TQ; Rohde D; Peter S
    Aktuelle Urol; 2010 Jan; 41 Suppl 1():S57-60. PubMed ID: 20094957
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeted therapy for metastatic renal cell carcinoma.
    Motzer RJ; Bukowski RM
    J Clin Oncol; 2006 Dec; 24(35):5601-8. PubMed ID: 17158546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-angiogenic therapy: concept to clinic.
    Young RJ; Reed MW
    Microcirculation; 2012 Feb; 19(2):115-25. PubMed ID: 22078005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adverse effects of anticancer agents that target the VEGF pathway.
    Chen HX; Cleck JN
    Nat Rev Clin Oncol; 2009 Aug; 6(8):465-77. PubMed ID: 19581909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Angiogenesis targeting in renal carcinomas].
    Pouessel D; Culine S
    Bull Cancer; 2007; 94(7 Suppl):F223-6. PubMed ID: 17965000
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
    Liu L; Cao Y; Chen C; Zhang X; McNabola A; Wilkie D; Wilhelm S; Lynch M; Carter C
    Cancer Res; 2006 Dec; 66(24):11851-8. PubMed ID: 17178882
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models.
    Zhu XD; Sun HC; Xu HX; Kong LQ; Chai ZT; Lu L; Zhang JB; Gao DM; Wang WQ; Zhang W; Zhuang PY; Wu WZ; Wang L; Tang ZY
    Angiogenesis; 2013 Oct; 16(4):809-20. PubMed ID: 23716000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution of systemic therapy of advanced hepatocellular carcinoma.
    Yau T; Chan P; Epstein R; Poon RT
    World J Gastroenterol; 2008 Nov; 14(42):6437-41. PubMed ID: 19030192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Ravaud A; Sire M
    Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
    [No Abstract]   [Full Text] [Related]  

  • 38. Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations?
    Sessa C; Guibal A; Del Conte G; Rüegg C
    Nat Clin Pract Oncol; 2008 Jul; 5(7):378-91. PubMed ID: 18560389
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RAIN-Droplet: a novel 3D in vitro angiogenesis model.
    Zeitlin BD; Dong Z; Nör JE
    Lab Invest; 2012 Jul; 92(7):988-98. PubMed ID: 22565576
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.
    Podar K; Anderson KC
    Curr Cancer Drug Targets; 2011 Nov; 11(9):1005-24. PubMed ID: 21933109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.